cholinergic pathways and the limitations of inhaled therapeutics · 2019. 5. 16. · cholinergic...
TRANSCRIPT
![Page 1: Cholinergic Pathways and the limitations of inhaled therapeutics · 2019. 5. 16. · Cholinergic Pathways and the limitations of inhaled therapeutics Reinoud Gosens, PhD 06 Sept 2016](https://reader036.vdocuments.us/reader036/viewer/2022081523/5fd9c7f5f244913f7929f70e/html5/thumbnails/1.jpg)
Cholinergic Pathways and the limitations of inhaled therapeutics
Reinoud Gosens, PhD 06 Sept 2016
Department of Molecular Pharmacology University of Groningen
Groningen Research Institute for Asthma and COPD
![Page 2: Cholinergic Pathways and the limitations of inhaled therapeutics · 2019. 5. 16. · Cholinergic Pathways and the limitations of inhaled therapeutics Reinoud Gosens, PhD 06 Sept 2016](https://reader036.vdocuments.us/reader036/viewer/2022081523/5fd9c7f5f244913f7929f70e/html5/thumbnails/2.jpg)
• Anatomy of the airway cholinergic system.
• Role in bronchoconstriction.
• Pro-inflammatory nature of acetylcholine.
• Contribution to lung function impairment and exacerbations in COPD and asthma.
Goals
![Page 3: Cholinergic Pathways and the limitations of inhaled therapeutics · 2019. 5. 16. · Cholinergic Pathways and the limitations of inhaled therapeutics Reinoud Gosens, PhD 06 Sept 2016](https://reader036.vdocuments.us/reader036/viewer/2022081523/5fd9c7f5f244913f7929f70e/html5/thumbnails/3.jpg)
![Page 4: Cholinergic Pathways and the limitations of inhaled therapeutics · 2019. 5. 16. · Cholinergic Pathways and the limitations of inhaled therapeutics Reinoud Gosens, PhD 06 Sept 2016](https://reader036.vdocuments.us/reader036/viewer/2022081523/5fd9c7f5f244913f7929f70e/html5/thumbnails/4.jpg)
Sensory and motor units in the vagal nerve
Kistemaker et al
Sensory nerve
Motor nerve
![Page 5: Cholinergic Pathways and the limitations of inhaled therapeutics · 2019. 5. 16. · Cholinergic Pathways and the limitations of inhaled therapeutics Reinoud Gosens, PhD 06 Sept 2016](https://reader036.vdocuments.us/reader036/viewer/2022081523/5fd9c7f5f244913f7929f70e/html5/thumbnails/5.jpg)
0
20
40
60
80
100
0,5 1 2 4 8 16 31 62,5
Con
trac
tile
Res
pons
es
EFS (Hz)
Largeairways
Smallairways
Cholinergic neurons are expressed in large and small airways
Time
Sopi et al
Airway
![Page 6: Cholinergic Pathways and the limitations of inhaled therapeutics · 2019. 5. 16. · Cholinergic Pathways and the limitations of inhaled therapeutics Reinoud Gosens, PhD 06 Sept 2016](https://reader036.vdocuments.us/reader036/viewer/2022081523/5fd9c7f5f244913f7929f70e/html5/thumbnails/6.jpg)
Muscarinic Nicotinic
Acetylcholine
ChAT
Acetyl CoA + Choline
Acetylcholine: synthesis and mode of action
![Page 7: Cholinergic Pathways and the limitations of inhaled therapeutics · 2019. 5. 16. · Cholinergic Pathways and the limitations of inhaled therapeutics Reinoud Gosens, PhD 06 Sept 2016](https://reader036.vdocuments.us/reader036/viewer/2022081523/5fd9c7f5f244913f7929f70e/html5/thumbnails/7.jpg)
The airway cholinergic system
![Page 8: Cholinergic Pathways and the limitations of inhaled therapeutics · 2019. 5. 16. · Cholinergic Pathways and the limitations of inhaled therapeutics Reinoud Gosens, PhD 06 Sept 2016](https://reader036.vdocuments.us/reader036/viewer/2022081523/5fd9c7f5f244913f7929f70e/html5/thumbnails/8.jpg)
The output of the airway cholinergic system is increased by inflammation
Sensory nerve
Motor nerve
![Page 9: Cholinergic Pathways and the limitations of inhaled therapeutics · 2019. 5. 16. · Cholinergic Pathways and the limitations of inhaled therapeutics Reinoud Gosens, PhD 06 Sept 2016](https://reader036.vdocuments.us/reader036/viewer/2022081523/5fd9c7f5f244913f7929f70e/html5/thumbnails/9.jpg)
The airway cholinergic system may contribute to inflammation
Kistemaker and Gosens, Trends Pharmacol Sci (2015)
![Page 10: Cholinergic Pathways and the limitations of inhaled therapeutics · 2019. 5. 16. · Cholinergic Pathways and the limitations of inhaled therapeutics Reinoud Gosens, PhD 06 Sept 2016](https://reader036.vdocuments.us/reader036/viewer/2022081523/5fd9c7f5f244913f7929f70e/html5/thumbnails/10.jpg)
![Page 11: Cholinergic Pathways and the limitations of inhaled therapeutics · 2019. 5. 16. · Cholinergic Pathways and the limitations of inhaled therapeutics Reinoud Gosens, PhD 06 Sept 2016](https://reader036.vdocuments.us/reader036/viewer/2022081523/5fd9c7f5f244913f7929f70e/html5/thumbnails/11.jpg)
Tiotropium Aclidinium
Glycopyrronium
Umeclidinium
Long-acting muscarinic antagonists (LAMA)
Compound Dose Frequency Tiotropium 5 µg Once daily Aclidinium 400 µg Twice daily Glycopyrronium 50 µg Once daily Umeclidinium 125 µg Once daily
![Page 12: Cholinergic Pathways and the limitations of inhaled therapeutics · 2019. 5. 16. · Cholinergic Pathways and the limitations of inhaled therapeutics Reinoud Gosens, PhD 06 Sept 2016](https://reader036.vdocuments.us/reader036/viewer/2022081523/5fd9c7f5f244913f7929f70e/html5/thumbnails/12.jpg)
The Ideal Bronchodilator
Airflow
Quality of life
Exercise endurance
Immediate onset Long duration of action Safe
Exacerbations
![Page 13: Cholinergic Pathways and the limitations of inhaled therapeutics · 2019. 5. 16. · Cholinergic Pathways and the limitations of inhaled therapeutics Reinoud Gosens, PhD 06 Sept 2016](https://reader036.vdocuments.us/reader036/viewer/2022081523/5fd9c7f5f244913f7929f70e/html5/thumbnails/13.jpg)
Tashkin et al., NEJM (2004) 55:289-294
Long-term impact of tiotropium on lung function
![Page 14: Cholinergic Pathways and the limitations of inhaled therapeutics · 2019. 5. 16. · Cholinergic Pathways and the limitations of inhaled therapeutics Reinoud Gosens, PhD 06 Sept 2016](https://reader036.vdocuments.us/reader036/viewer/2022081523/5fd9c7f5f244913f7929f70e/html5/thumbnails/14.jpg)
Impact of LAMAs on COPD exacerbations
*p≤0.05; **p≤0.01; ***p≤0.001 Novartis, data on file
Kerwin et al., Eur Respir J (2012)
![Page 15: Cholinergic Pathways and the limitations of inhaled therapeutics · 2019. 5. 16. · Cholinergic Pathways and the limitations of inhaled therapeutics Reinoud Gosens, PhD 06 Sept 2016](https://reader036.vdocuments.us/reader036/viewer/2022081523/5fd9c7f5f244913f7929f70e/html5/thumbnails/15.jpg)
Impact of LAMAs on Asthma (lung function, exacerbations)
*p≤0.05; **p≤0.01; ***p≤0.001 Novartis, data on file
Severe asthma; on top of corticosteroids+ β2-agonists
Kerstjens, et al. NEJM (2012)
![Page 16: Cholinergic Pathways and the limitations of inhaled therapeutics · 2019. 5. 16. · Cholinergic Pathways and the limitations of inhaled therapeutics Reinoud Gosens, PhD 06 Sept 2016](https://reader036.vdocuments.us/reader036/viewer/2022081523/5fd9c7f5f244913f7929f70e/html5/thumbnails/16.jpg)
0
5
10
15
20
25
30
35
FEV
1 (%
rela
tive
chan
ge)
Bronchodilator treatment: reality vs. the ideal situation
![Page 17: Cholinergic Pathways and the limitations of inhaled therapeutics · 2019. 5. 16. · Cholinergic Pathways and the limitations of inhaled therapeutics Reinoud Gosens, PhD 06 Sept 2016](https://reader036.vdocuments.us/reader036/viewer/2022081523/5fd9c7f5f244913f7929f70e/html5/thumbnails/17.jpg)
• The airway cholinergic system is expressed in both large and small airways.
• Neuronal acetylcholine regulates bronchoconstriction with a predominant role for the M3 receptor.
• Inflammation can increase acetylcholine release which in turn may contribute to inflammation.
• Acetylcholine contributes to lung function impairment and exacerbations in COPD and asthma.
Summary - Conclusions